Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 06-05-2003, 02:55 AM   #1
Posts: n/a
Omnitarg (2C4) is a monoclonal antibody and the first in a new class of agents developed by Genentech known as HER dimerization inhibitors (HDIs). It was developed to bind to the HER-2 receptor and block the interaction between HER-2 and other HER family members (i.e. HER1/EGFR HER2 HER3 and HER4). Technically it is designed to target tumors that have normal " rather than ""overexpressed" " HER2 protein. It is relevant because it may one day represent the Herceptin equivalent"" treatment for patients who are not HER-2 positive or who are not ""strongly"" HER-2 positive.

Importantly" the positive study data relates not only to breast cancer but to other cancers as well (e.g. prostate lung ovarian colon pancreas and sarcoma).
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 08:25 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter